| Reviews |
 |
|
|
|
|
Reviews to:
Date: Saturday, 19. December 2015
Author: Gast
Review:
A Second Class stamp hermes birkin Celgene\'s new multiple myeloma treatment, Pomalyst, sold $66 million in its first full quarter of sales. The drug was approved by the U.S. Food and Drug Administration in February and is expected to reach the billion-dollar sales mark by 2016.
Evaluation:  |
|
|
|
| Shopping Cart |
 |
|
| You do not have any products in your shopping cart yet. |
|
|
Customer group:Guest
|
|
|
|
